|
|
Post by mannmade on Jun 11, 2014 9:10:43 GMT -5
|
|
|
|
Post by nemzter on Jun 11, 2014 9:18:25 GMT -5
MannKind Corp. (NASDAQ: MNKD) may not be among the largest of the biotechs by any stretch with its $4 billion market cap. Still, it remains one of the biggest battleground stocks for bulls against short sellers. This is due to its inhalable insulin drug review at the FDA, a process that has been up for grabs for years — and not without controversy. MannKind’s short interest ticked up to 68,246,601 shares at the end of May from 68,035,239 shares short in mid-May. This was just shy of the peak in the short interest of the past year, and the short interest is up 50% from last December. Read more: Short Sellers Remain Vigilant Against Top Biotech Stocks - MannKind Corp (NASDAQ:MNKD) - 24/7 Wall St. 247wallst.com/healthcare-business/2014/06/11/short-sellers-remain-vigilant-against-top-biotech-stocks/#ixzz34L9sTn7x Follow us: @247wallst on Twitter | 247wallst on Facebook |
|
|
|
Post by nemzter on Jun 11, 2014 9:19:18 GMT -5
Watching this everyday and can't wait for the SQUEEZE!
|
|
|
|
Post by kc on Jun 11, 2014 9:54:10 GMT -5
Great article.
|
|
